bit.bio raises $25 million to expand human cell models

The Cambridge-based biotech company raised $25 million in a Series D round and plans to add cell types to its research portfolio and widen access to its models. The reports describe applications in drug research and testing, and note growth in customer and order metrics.

• bit.bio raised $25 million in a Series D round, with participation from existing investor M&G Investments and Abcam founder and former CEO Jonathan Milner.· 2 sources
• Its ioCells portfolio includes more than 50 human cell types, and the company plans to use the funding to expand the range and availability of its models.· 2 sources
• TNW reported year-on-year increases in paid vial volumes, orders and active customers; it said the company plans to bring more cell types to market using existing manufacturing capacity.· 1 source